Skip to main content
. 2019 Mar 22;10:537. doi: 10.3389/fimmu.2019.00537

Figure 3.

Figure 3

Serum MBL/L-ficolin levels in IgAN Patients and Healthy Controls with different genotypes of rs1800450 or rs7851686. (A) MBL levels distributed in rs1800450 of 282 IgAN patients. The median MBL level of the AA group [(1 (0–6) ng/ml, p < 0.001] and GA group [(273 (0–6,016) ng/ml, p < 0.001] were significantly lower than the GG group [(1,484 (124–16,574) ng/ml]; (B) L-ficolin levels distributed in rs7851696 of 282 IgAN patients. The median serum L-ficolin levels of TT [(1,357 (123–3,669) ng/ml, p = 0.003] and GT [(2,660 (334–8,807) ng/ml, p = 0.007] were lower than GG groups [(3,236 (785–14,417) ng/ml]; (C) MBL levels distributed in rs1800450 of 60 healthy control. The median MBL level of the AA group [0 (0–1.2) ng/ml, P = 0.001] was also significantly lower than the GG group [1,259 (147–2,409) ng/ml], followed by GA group [255 (1–1786) ng/ml, P < 0.001]; (D) L-ficolin levels distributed in rs7851696 of 60 healthy control. The median serum levels of L-ficolin were also lowest in TT [2,039 (1,839–3,497) ng/ml, P = 0.04), followed by GT [2,974 (650–4,577) ng/ml, P = 0.1], while compared to GG [3,631 (1,471–6,025) ng/ml] in 60 healthy controls. (E) Serum deficiency of MBL/L-ficolin among three genotype groups of rs1800450 or rs7851696 in 282 IgAN patients and 60 healthy controls. ***P < 0.001.